se eri a buenos aires ti potevi fare un giro in porta venezia (giardini fantastici con museo della scienza e planetario dentro), poi facevi un salto nella sede di rappresentanza dell'amata (via palestro.. proprio li di fronte) e con cinque minuti di passeggiata eri in san babila.. .da li la strada la conosci..
se eri a buenos aires ti potevi fare un giro in porta venezia (giardini fantastici con museo della scienza e planetario dentro), poi facevi un salto nella sede di rappresentanza dell'amata (via palestro.. proprio li di fronte) e con cinque minuti di passeggiata eri in san babila.. .da li la strada la conosci..
Thousand forseLicensing-out existing MPCs
THERAMetrics is finally experiencing success in its efforts to license-out its Medical Product Candidates (MPCs). In March 2015, the Company
signed a licensing agreement with Centurion Pharma (Istanbul, Turkey) for Aviptadil, THERAMetrics’ drug candidate for Sarcoidosis. Under the
terms of this agreement the two companies will cooperate in the development and registration of Aviptadil for the treatment of Sarcoidosis in
Turkey and in other neighboring markets. At the same time, both companies have signed Letters of Intent for contract research services for:
• the development of Aviptadil in Sarcoidosis in Turkey including design, organization and execution of the clinical development plan
for the registration of Aviptadil in Turkey
• the future development of Aviptadil in additional geographical regions
• the joint research and development on different projects employing THERAMetrics’ DRR2.0 Drug Repositioning technology
Cash flows in 2015 from this agreement will be less than TEUR 200, however, the potential for future royalties if the drug reaches the market
could be significant.
In addition to the contract with Centurion, the Company is currently negotiation a number of similar agreements for its other MPCs.
qualcuno capisce cosa significa TEUR 200
Licensing-out existing MPCs
THERAMetrics is finally experiencing success in its efforts to license-out its Medical Product Candidates (MPCs). In March 2015, the Company
signed a licensing agreement with Centurion Pharma (Istanbul, Turkey) for Aviptadil, THERAMetrics’ drug candidate for Sarcoidosis. Under the
terms of this agreement the two companies will cooperate in the development and registration of Aviptadil for the treatment of Sarcoidosis in
Turkey and in other neighboring markets. At the same time, both companies have signed Letters of Intent for contract research services for:
• the development of Aviptadil in Sarcoidosis in Turkey including design, organization and execution of the clinical development plan
for the registration of Aviptadil in Turkey
• the future development of Aviptadil in additional geographical regions
• the joint research and development on different projects employing THERAMetrics’ DRR2.0 Drug Repositioning technology
Cash flows in 2015 from this agreement will be less than TEUR 200, however, the potential for future royalties if the drug reaches the market
could be significant.
In addition to the contract with Centurion, the Company is currently negotiation a number of similar agreements for its other MPCs.
qualcuno capisce cosa significa TEUR 200
Thousand forse
si si
Appena lo vede Vincislato che l'accordo è di 200k euro per il 2015 viene "di là" a prendervi in giro per 15 giorni di fila...
